The Global Allergy Treatment Market size was valued at USD YY million in 2021 and is estimated to reach USD YY million by 2030, growing at a CAGR of 4.8% during the forecast period (2023-2030).
Allergy treatment is a medical procedure that prevents allergic reactions to allergens such as pollens, molds, animal dander, latex, insects, food and medications. They cause the immune system to release histamine, which causes inflammation, rashes, itchiness, sneezing, runny nose, and red eyes.
They can also cause hay fever, asthma, rhinitis, and skin, food, and eye allergies. Allergy treatment includes anti-allergic medications and immunotherapy, which can be taken orally, through inhalers, or intranasally. These treatment methods help to reduce sensitivity and inflammation, reduce symptoms, and improve the patient's quality of life.
Source: DataM Intelligence Analysis (2021)
The increasing prevalence of various allergies worldwide, positive efforts by governments and non-governmental organizations (NGOs) to educate the public about the negative effects of allergies and the best ways to treat them, launching new products with key marketers' approval, increasing clinical trials and rising demand for over-the-counter (OTC) drugs, combined with a growing consumer preference for self-medication are the factors to drive the market in the forecast period.
The Increasing Clinical Trials for Allergy Drugs are Expected to Drive Market Growth.
Revelation Biosciences dosed and enrolled the first patient in a Phase Ib clinical study to assess the potential utility of REVTx-99 in treating patients with allergic rhinitis and chronic nasal congestion without polyps in January 2022. The clinical trial is being carried out in Australia.
Additionally, ABVC Biopharma announced in May 2022 that BioKey, a wholly-owned subsidiary of the company based in Fremont, California, had entered into a $3.0 million clinical services contract with NeuCen BioMed Co. Ltd. to guide two NeuCen drug products, CEN501 and NEU001, through Phase II clinical studies under US FDA IND regulatory requirements. CEN501 is a nasal strip used as a local nasal immunotherapy (LNIT) treatment for patients with mite-induced allergic rhinitis.
Furthermore, Altamira Therapeutics announced the completion of patient enrollment in its Bentrio trial in house dust mite ("HDM") allergic rhinitis in March 2022. The trial's top-line results are expected to be released in the second quarter of 2022. Therefore, the rising clinical trials raised the demand for drugs to treat allergies. Thus, from the above factors, the market is expected to drive in the forecast period.
Side Effects of Allergy Shots are Expected to Hamper the Market Growth.
Allergy shots, like any other medication regimen, may have side effects. Allergy shots are also more time-consuming than standard medication regimens. It is critical to keep this time commitment in mind when considering allergy shots. Allergy injections may cause several side effects. Some common local side effects include redness and warm skin at the injection site and swelling or pain at the injection site.
Shortness of breath or wheezing, light-headedness or dizziness, hives, and sudden itching are all serious, systemic reactions to be aware of. Most serious reactions will occur within 30 minutes of your initial injection, so the patients are strongly advised to remain in the clinic after the initial administration. Thus, from the above factors, the market is expected to be hampered in the forecast period.
The coronavirus pandemic has moderately impacted the allergy treatment market. Allergic diseases are common and cause significant morbidity and financial burden. Thus, optimizing the care of allergic patients during the pandemic is critical.
As a result, guidelines for allergic conditions were developed, as well as a series of international expert panel/consensus documents. The European Academy of Allergy and Clinical Immunology (EAACI) has quickly released high-quality information, position papers, and clinical recommendations for treating allergic diseases.
Moreover, implementing remote care was one of the most relevant recommendations proposed by international societies to assess disease control, promote patient compliance, monitor biologic self-administration, and provide patient education. In general, medical consensus and guidelines are developed based on quality evidence, but given the nature of the pandemic, issuing recommendations supported by prior evidence was not feasible.
For example, in response to the urgent need to assess the impact of the COVID-19 pandemic on the care of allergic patients, EAACI developed an international survey to collect real-life experience data. With a focus on practical considerations, the goal was to provide information that could lead to future management and recommendations even after the pandemic.
Additionally, prioritizing face-to-face care for patients with significant in-person care needs and favoring the use of remote tools in situations that could be managed effectively was recommended by international guidance. Thus, from the above factors, the market got affected and is expected to boost in the forecast period.
The Immunotherapy Segment is Expected to Hold the Largest Market Share in Allergy Treatment Market
The immunotherapy segment accounted for the largest market share in 2021. Immunotherapy is an excellent allergy relief option for anyone suffering from severe symptoms, particularly those with seasonal allergies. It works by gradually exposing the patient to increasing levels of an allergen to help the immune system build a tolerance to it. This relieves a wide range of allergy symptoms and even prevents the development of new allergies. For instance, subcutaneous immunotherapy (SCIT) is the most effective and widely used allergy immunotherapy. So far, SCIT is the only treatment that alters the immune system and provides systemic relief. SCIT helps to prevent the emergence of new allergies and asthma attacks.
Furthermore, the innovative launch of immunotherapy products and rising approval are major factors boosting the segments. For instance, on July 29, 2021, the FDA approved Nucala (mepolizumab) as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This is a new indication for mepolizumab, a monoclonal antibody that targets interleukin-5 (IL-5). Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.
Source: DataM Intelligence Analysis (2021)
North America Region Holds the Largest Market Share in the Global Allergy Treatment Market
North America region accounted for the largest market share in 2021. The increasing allergy prevalence, high awareness of allergic disorders, immunotherapies, epinephrine autoinjectors, and inhalers have increased the adoption of innovative allergy medicines and medical devices. Furthermore, rising FDA approvals and product launches by key market players will drive the region's growth during the forecast period.
For instance, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved Amgen and AstraZeneca's Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
In addition to the United States, the Canadian government focuses on providing Canadians with the information they need to make healthy and safe food choices. The CFIA (Canadian Food Inspection Agency) and Health Canada collaborate with provincial, municipal, and territorial partners and sectors to achieve this goal. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.
Major key players in the allergy treatment market are GlaxoSmithKline plc, Teva Pharmaceuticals, Sallergenes Greer, Allergy Therapeutics, Sanofi SA, Sunovion Pharmaceuticals Inc., Johnson & Johnson, Merck KGaA, F. Hoffmann-La Roche AG and Allergan plc
On March 22, 2021, Glenmark Pharmaceuticals announced that its Swiss subsidiary Glenmark Specialty S.A. and a Bausch Health Companies Inc. affiliate have entered into an exclusive licensing agreement for the commercialization of Glenmark's innovative nasal spray RYALTRIS, which is currently under review by Health Canada.
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products.
The Pharmaceuticals business discovers, develops and commercializes medicines to treat acute and chronic diseases. The Vaccines business provides vaccines for people of all ages, from babies and adolescents to adults and older people. It has a portfolio of medicines for respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty Products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Advair: Advair is a mixture of a steroid (fluticasone) and a long-acting bronchodilator (salmeterol). It is used to treat asthma and COPD
The Global Allergy Treatment Market Report Would Provide Access to Approx. 45+ Market Data Tables, 40+ Figures and 180 Pages.